ConvaTec Group Plc (CNVVF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ConvaTec Group Plc (CNVVF) with AI Score 49/100 (Weak). Convatec Group PLC develops, manufactures, and sells medical products and technologies for chronic condition management. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026ConvaTec Group Plc (CNVVF) Healthcare & Pipeline Overview
Convatec Group PLC, a global medical technology company, focuses on providing solutions for chronic conditions, including advanced wound care, ostomy care, continence care, and infusion care. With a presence in Europe, North America, and other international markets, Convatec serves healthcare providers, patients, and manufacturers through direct sales and distribution networks.
Investment Thesis
Convatec Group PLC presents a compelling investment case based on its established position in the chronic care market and its diversified product portfolio. With a market capitalization of $7.42 billion, the company benefits from a gross margin of 56.3% and an ROE of 10.9%. Growth catalysts include the increasing prevalence of chronic conditions globally and the company's focus on innovation and new product development. However, investors should be aware of the company's debt-to-equity ratio of 100.00 and the competitive landscape. Convatec's ability to maintain its market share and successfully launch new products will be crucial for future growth.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $7.42 billion indicates a significant presence in the medical instruments and supplies market.
- Gross margin of 56.3% demonstrates strong pricing power and efficient cost management.
- Return on Equity (ROE) of 10.9% reflects the company's profitability and efficient use of shareholder equity.
- Debt-to-Equity ratio of 100.00 indicates a moderate level of financial leverage.
- Profit Margin of 7.2% shows the company's ability to generate profit from revenue.
Competitors & Peers
Strengths
- Strong market position in chronic care solutions.
- Diversified product portfolio.
- Global distribution network.
- Established brand reputation.
Weaknesses
- High debt-to-equity ratio.
- Dependence on key products and markets.
- Exposure to regulatory risks.
- Limited presence in emerging markets.
Catalysts
- Ongoing: Increasing prevalence of chronic conditions such as diabetes and obesity driving demand for Convatec's products.
- Upcoming: Potential new product launches in advanced wound care and ostomy care segments in late 2026.
- Ongoing: Expansion into emerging markets, particularly in Asia-Pacific and Latin America.
- Ongoing: Strategic partnerships with healthcare providers and research institutions.
Risks
- Potential: Intense competition from established players in the medical device industry.
- Potential: Pricing pressures from healthcare providers and payers.
- Ongoing: Regulatory risks associated with medical device approvals and compliance.
- Potential: Product liability claims and recalls.
- Ongoing: Fluctuations in currency exchange rates.
Growth Opportunities
- Expansion in Emerging Markets: Convatec has the opportunity to expand its presence in emerging markets, where the demand for advanced medical solutions is growing rapidly due to increasing healthcare expenditure and rising awareness of chronic disease management. Focusing on key markets in Asia-Pacific and Latin America could drive significant revenue growth. This expansion could contribute an additional 10% to overall revenue within the next 3-5 years.
- New Product Development and Innovation: Investing in research and development to launch innovative products and solutions in its core areas of advanced wound care, ostomy care, continence care, and infusion care can drive organic growth. The company can focus on developing products that address unmet needs in the market and offer superior clinical outcomes. Successful product launches could increase revenue by 8% annually.
- Strategic Acquisitions: Convatec can pursue strategic acquisitions to expand its product portfolio, enter new markets, and gain access to new technologies. Acquiring companies with complementary products or technologies can strengthen Convatec's competitive position and drive revenue synergies. A well-executed acquisition strategy could add 5-7% to revenue growth.
- Digital Health Solutions: Integrating digital health solutions into its product offerings can enhance patient engagement, improve clinical outcomes, and drive revenue growth. Developing mobile apps, remote monitoring devices, and telehealth platforms can provide patients with personalized care and support. The digital health market is expected to reach $379 billion by 2024, presenting a significant opportunity for Convatec.
- Partnerships and Collaborations: Collaborating with healthcare providers, research institutions, and other companies can accelerate innovation, expand market reach, and drive revenue growth. Partnering with leading hospitals and clinics can provide Convatec with access to clinical data and expertise, enabling the company to develop more effective solutions. Strategic partnerships could boost revenue by 6% per year.
Opportunities
- Expansion in emerging markets.
- New product development and innovation.
- Strategic acquisitions.
- Digital health solutions.
Threats
- Intense competition.
- Pricing pressures.
- Product liability claims.
- Economic downturns.
Competitive Advantages
- Established brand reputation and customer loyalty in the chronic care market.
- Diversified product portfolio across multiple therapeutic areas.
- Global distribution network and presence in key markets.
- Strong relationships with healthcare providers and patients.
About CNVVF
Convatec Group PLC, founded in 1978 and headquartered in London, is a global medical products and technologies company focused on solutions for the management of chronic conditions. The company operates in four key areas: Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. Its Advanced Wound Care products address acute and chronic wounds resulting from conditions like diabetes, traumatic injuries, and burns. The Ostomy Care division provides devices, accessories, and services for individuals with a stoma due to colorectal cancer, bladder cancer, inflammatory bowel disease, or trauma. Convatec's Continence Care offerings cater to individuals with urinary continence issues arising from spinal cord injuries, neurological diseases, prostate enlargement, or other causes. The Infusion Care segment provides disposable infusion sets for insulin pumps used in diabetes management and continuous infusion treatments for conditions like Parkinson's disease. Convatec distributes its products directly and through distributors and wholesalers to pharmacies, hospitals, and other healthcare providers, serving a broad customer base including healthcare professionals, patients, and manufacturers across Europe, North America, and other international markets.
What They Do
- Develops advanced wound care products for chronic and acute wounds.
- Manufactures ostomy care solutions for individuals with a stoma.
- Offers continence care products for urinary continence issues.
- Provides infusion care solutions for diabetes insulin pumps and continuous infusion treatments.
- Sells products to pharmacies, hospitals, and healthcare providers.
- Distributes products directly and through wholesalers.
Business Model
- Develops and manufactures medical products and technologies.
- Sells products directly to healthcare providers and patients.
- Distributes products through wholesalers and distributors.
- Generates revenue from product sales and related services.
Industry Context
Convatec Group PLC operates within the global medical instruments and supplies industry, which is characterized by increasing demand for advanced medical technologies and solutions for chronic diseases. The industry is driven by factors such as an aging population, rising prevalence of chronic conditions like diabetes and obesity, and technological advancements in medical devices. Convatec competes with other major players in the market, focusing on innovation and product differentiation to maintain its competitive edge. The global medical device market is projected to reach $600 billion by 2025, with a CAGR of 5.4%.
Key Customers
- Healthcare providers (hospitals, clinics, and nursing homes)
- Patients with chronic conditions (diabetes, wounds, ostomies, continence issues)
- Pharmacies and retailers
- Manufacturers
Financials
Chart & Info
ConvaTec Group Plc (CNVVF) stock price: Price data unavailable
Latest News
-
Convatec Group PLC (CNVVY) Full Year 2025 Earnings Call Highlights: Strong Growth Amid Challenges
Yahoo! Finance: CNVVF News · Mar 5, 2026
-
ConvaTec Group H2 Earnings Call Highlights
Yahoo! Finance: CNVVF News · Feb 24, 2026
-
ConvaTec Leads FTSE 100 Gainers on Higher Revenue, Raised Outlook
Yahoo! Finance: CNVVF News · Feb 24, 2026
-
$3.8 Billion Negative Pressure Wound Therapy (NPWT) Devices Market Assessment, 2030 - Featuring Solventum, Smith+Nephew, Cardinal Health, Molnlycke Health Care, ConvaTec Group and Other Key Players
GlobeNewswire · Feb 19, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNVVF.
Price Targets
Wall Street price target analysis for CNVVF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CNVVF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Convatec Group PLC (CNVVY) Full Year 2025 Earnings Call Highlights: Strong Growth Amid Challenges
ConvaTec Group H2 Earnings Call Highlights
ConvaTec Leads FTSE 100 Gainers on Higher Revenue, Raised Outlook
$3.8 Billion Negative Pressure Wound Therapy (NPWT) Devices Market Assessment, 2030 - Featuring Solventum, Smith+Nephew, Cardinal Health, Molnlycke Health Care, ConvaTec Group and Other Key Players
CNVVF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing companies that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be undergoing financial distress, have limited operating history, or choose not to comply with stricter disclosure standards. As a result, information available to investors may be limited, and the risk of investing in these companies is generally higher compared to those listed on regulated exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before considering investments in OTC Other companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure may obscure the true financial health of the company.
- Lower trading volume can lead to price volatility and difficulty in executing trades.
- Potential for fraud or manipulation is higher due to less stringent regulatory oversight.
- The company may be undergoing financial distress or have a limited operating history.
- OTC stocks are generally more susceptible to pump-and-dump schemes.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review any available news articles or press releases about the company.
- Check the company's registration status with regulatory agencies.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has been in operation since 1978, suggesting a degree of stability.
- Convatec Group PLC has a substantial market capitalization of $7.42 billion.
- The company has a global presence and serves a wide range of customers.
- Convatec Group PLC has a profit margin of 7.2%.
What Investors Ask About ConvaTec Group Plc (CNVVF)
What does Convatec Group PLC do?
Convatec Group PLC is a global medical technology company focused on developing, manufacturing, and marketing products and services for the management of chronic conditions. The company operates in four key segments: Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. Its products are used by healthcare providers and patients to manage conditions such as chronic wounds, ostomies, urinary incontinence, and diabetes. Convatec sells its products through a combination of direct sales and distribution networks, serving customers in Europe, North America, and other international markets. The company's business model focuses on providing innovative and clinically effective solutions that improve patient outcomes and quality of life.
What do analysts say about CNVVF stock?
Analyst coverage of CNVVF is limited due to its OTC listing. However, considering Convatec Group PLC's fundamentals, the company's valuation is influenced by its growth prospects in the chronic care market and its ability to maintain profitability. Key metrics to watch include revenue growth, gross margin, and earnings per share. Investors should also monitor the company's debt levels and cash flow generation. Analyst consensus on Convatec's stock performance is mixed, with some expressing optimism about the company's long-term growth potential and others highlighting the risks associated with its OTC listing and competitive landscape. There is no consensus to buy or sell.
What are the main risks for CNVVF?
Investing in Convatec Group PLC (CNVVF) carries several risks, including its listing on the OTC market, which entails lower liquidity and less stringent regulatory oversight compared to major exchanges. The company also faces competition from larger, more established players in the medical device industry, which could put pressure on pricing and market share. Regulatory risks associated with medical device approvals and compliance are also a concern. Furthermore, fluctuations in currency exchange rates could impact the company's financial performance, as it operates in multiple countries. Product liability claims and recalls are also potential risks that could negatively affect the company's reputation and financial results. Investors should carefully consider these risks before investing in CNVVF.
What are the key factors to evaluate for CNVVF?
ConvaTec Group Plc (CNVVF) currently holds an AI score of 49/100, indicating low score. Key strength: Strong market position in chronic care solutions.. Primary risk to monitor: Potential: Intense competition from established players in the medical device industry.. This is not financial advice.
How frequently does CNVVF data refresh on this page?
CNVVF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CNVVF's recent stock price performance?
Recent price movement in ConvaTec Group Plc (CNVVF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong market position in chronic care solutions.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CNVVF overvalued or undervalued right now?
Determining whether ConvaTec Group Plc (CNVVF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CNVVF?
Before investing in ConvaTec Group Plc (CNVVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis pending, so some insights may be incomplete.